Nicotine vaping continues to outperform FDA-approved smoking cessation therapies in well-designed studies, including a new clinical trial conducted in Australia. This growing body of evidence badly ...

IRVINE, Calif., Feb. 10, 2026 /PRNewswire/ -- Qnovia, Inc., a pharmaceutical and medtech company revolutionizing inhaled therapeutics, today announced positive results from its Phase 1 clinical trial ...

Please provide your email address to receive an email when new articles are posted on . About 28% of those receiving vaporized nicotine products achieved 6-month abstinence vs. 9.6% of those receiving ...

Compared with the nicotine replacement therapy group, self-reported adverse events occurred less often in the vaporized group. HealthDay News — In a socially disadvantaged population, vaporized ...

Of 400 surveys mailed, 203 were completed. Twelve of the 400 were no longer in practice resulting in a return rate of 52% (203/388). The majority of respondents were white (77%), female (53%), board ...

Please provide your email address to receive an email when new articles are posted on . There is a current lack of new, approved smoking cessation therapies. The RespiRx Nicotine Inhaler may address ...